Zygel (cannabidiol gel) / Zynerba, Paragon Biosci  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zygel (cannabidiol gel) / Paragon Biosci
ACTRN12621000874819: Clinical study of cannabidiol in children, adolescents and young adults with Fragile X syndrome (RECONNECT)

Recruiting
3
204
 
Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd
Fragile X Syndrome
 
 
2021-002542-33: Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children, adolescents and young adults with a certain hereditary disease called Fragile X Syndrome

Not yet recruiting
3
204
Europe
ZYN002, Transdermal gel
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 gene. FXS is most commonly caused by silencing of the FMR1 gene due to a trinucleotide repeat expansion. In FXS patients, the relative absence of functional FMRP is associated with critical impairments in neurodevelopment and learning, as well as disruption to other neuronal and non-neuronal functions., Fragile X syndrome (FXS) is a rare disease caused by lack of Fragile X Messenger Ribonucleoprotein 1 due to a faulty gene. It mainly causes learning difficulties in patients., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
RECONNECT, NCT04977986: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
CONNECT-FX, NCT03614663: Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X

Checkmark Top-line data from CONNECT-FX trial in fragile X syndrome
Jun 2020 - Jun 2020: Top-line data from CONNECT-FX trial in fragile X syndrome
Completed
2/3
212
US, RoW
ZYN002 - Cannabidiol Transdermal Gel, Placebo Transdermal Gel, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
06/20
06/20
NCT03802799: Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

Enrolling by invitation
2/3
450
Europe, US, RoW
ZYN002 - Cannabidiol Transdermal Gel, Cannabidiol Transdermal Gel
Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
08/27
08/27

Download Options